We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TCOM icon
176
Trip.com Group
TCOM
$25.8B
-5,484
Closed -$273K
TERN
177
DELISTED
Terns Pharmaceuticals
TERN
-114,307
Closed -$6.03M
UNP icon
178
Union Pacific
UNP
$172B
-3,658
Closed -$888K
WDAY icon
179
Workday
WDAY
$47.2B
-8,286
Closed -$1.08M
XOMA
180
DELISTED
Xoma
XOMA
-46,814
Closed -$1.47M
BBOT
181
BridgeBio Oncology
BBOT
$720M
-78,187
Closed -$700K
RDDT icon
182
Reddit
RDDT
$29.7B
-6,900
Closed -$929K
GEV icon
183
GE Vernova
GEV
$251B
-1,218
Closed -$1.06M
PVLA
184
Palvella Therapeutics
PVLA
$2.27B
-5,903
Closed -$736K
AMRZ
185
Amrize Ltd
AMRZ
$24B
-17,068
Closed -$956K

Similar funds

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.